DEPARTMENT OF HEALTH & HUMAN SERVICES

PUBLIC HEALTH SERVICE
NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:
Office of Laboratory Animal Welfare
Rockledge One, Suite 360
6705 Rockledge Drive - MSC 7982
Bethesda, Maryland 20892-7982
Home Page: http://grants.nih.gov/grants/olaw/olaw.htm

FOR EXPRESS MAIL:
Office of Laboratory Animal Welfare
Rockledge One, Suite 360
6705 Rockledge Drive
Bethesda, Maryland 20817
Telephone: (301) 496-7163
Facsimile: (301) 402-7065

May 23, 2018

Alka Chandna, Ph.D.
Senior Researcher
People for Ethical Treatment of Animals
501 Front Street
Norfolk, Virginia 23510

Via e-mail: AlkaC@peta.org

Dear Dr. Chandna,

The Office of Laboratory Animal Welfare (OLAW) has completed its investigation of your February 28, 2018 allegation of noncompliance with the PHS Policy on Humane Care and Use of Laboratory Animals at the University of Nebraska Medical Center. The following findings were made:

- The matter was self-reported by the institution the following morning on March 1, 2018.
- Ten nonhuman primates were inadvertently given the wrong antiretroviral drug for five months because the wrong drug was ordered from the supplier. This incorrect drug has been used as a neuroprotectant.
- There was confusion on the part of the laboratory staff and the supplier due to similarities in the names of the drugs/abbreviations and the wrong one was shipped.
- There were no adverse effects exhibited by the primates.
- All of the animals were euthanized during the course of the experiment as an approved part of the protocol.
- The immediate action taken upon discovery consisted of the Principal Investigator notifying the Institutional Animal Care and Use Committee and directing the laboratory staff to stop using the incorrect drug.
- A standard operating procedure was developed by the laboratory to ensure that all drugs are validated before using in animals.
- The correct drug was received and the study continued according to the approved protocol.
- At the request of the Institutional Official, two external experts will review the procedures for handling drugs used in animals to ensure best practices are being employed.
- A special team was created to enhance the expertise, training, and skill of staff providing care and use of nonhuman primates.

OLAW accepted the institutional actions taken to correct and prevent this situation and has closed the inquiry. No further action will be taken in this matter. Thank you for your interest in animal welfare.

Sincerely,

(b) (6)

Axel Wolff, M.S., D.V.M.
Deputy Director
Office of Laboratory Animal Welfare

DEPARTMENT OF HEALTH & HUMAN SERVICES

PUBLIC HEALTH SERVICE
NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:
Office of Laboratory Animal Welfare
Rockledge One, Suite 360
6705 Rockledge Drive - MSC 7982
Bethesda, Maryland 20892-7982
Home Page: http://grants.nih.gov/grants/olaw/olaw.htm

FOR EXPRESS MAIL:
Office of Laboratory Animal Welfare
Rockledge One, Suite 360
6705 Rockledge Drive
Bethesda, Maryland 20817
Telephone: (301) 496-7163
Facsimile: (301) 402-7065

May 23, 2018

Re: Animal Welfare Assurance
#A3294-01 (OLAW Case 2F)

Dr. Jennifer Larsen
Vice Chancellor for Research
Louise and Morton Degen Professor
of Internal Medicine
University of Nebraska Medical Center
987878 University Nebraska Medical Center
Omaha, NE 68198-7878

Dear Dr. Larsen,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your May 22, 2018 letter reporting an instance of noncompliance with the PHS Policy on Humane Care and Use of Laboratory Animals at the University of Nebraska Medical Center, following up on an initial telephone report on March 1, 2018. According to the information provided, OLAW understands that ten nonhuman primates inadvertently received the wrong antiretroviral drug for five months because the wrong drug was ordered from the supplier. The laboratory staff failed to verify which drug was being ordered and there was also confusion at the vendor due to similarities between the drug names/abbreviations. There were no adverse effects exhibited by the primates and all were euthanized during the course of the experiment as an approved part of the protocol.

The immediate action taken upon discovery consisted of the Principal Investigator notifying the Institutional Animal Care and Use Committee (IACUC) and directing the laboratory to stop using the incorrect drug. A standard operating procedure was developed by the laboratory to ensure that all drugs are validated before using on animals. The correct drug was received and the study continued according to the approved protocol. The IACUC directed the laboratory to clearly label all drugs and to carefully validate all drugs when ordering, receiving, and prior to use. Detailed information about the drug must be in place. The Institutional Official (IO) invited two external experts to review the procedures for handling drugs used in animals to ensure best practices are being employed. The IO also asked the IACUC to assess whether the current policies for determining training and experience of staff working with primates are adequate. A special team was created to enhance the expertise, training, and skill of staff providing care and use of nonhuman primates.

Based on its assessment of this explanation, OLAW understands that measures have been implemented to correct and prevent recurrence of this problem. OLAW concurs with the actions taken by the IACUC to comply with the PHS Policy. Note that on February 28, 2018, OLAW was contacted by the People for the Ethical Treatment of Animals about this matter and our assessment will be shared with this organization. For completeness of the file, please provide the recommendations from the pharmacologics handling subject matter experts as well as any other policy changes. We appreciate having been informed about this matter and find no cause for further action by this Office.

Sincerely,

(b) (6)

Axel Wolff, M.S., D.V.M.
Deputy Director
Office of Laboratory Animal Welfare

cc: IACUC Chair
John Bradfield, D.V.M., Ph.D., Director, Comparative Medicine
Jennifer Schermerhorn, GMS, NIDA

University of Nebraska Medical Center

OFFICE OF THE VICE CHANCELLOR FOR RESEARCH

Date: May 22, 2018

Axel V. Wolff, M.S., D.V.M.,
Director, Division of Compliance Oversight
Office of Laboratory Animal Welfare
National Institutes of Health
Rockledge 1, Suite 360, MSC 7982
6705 Rockledge Drive
Bethesda, MD 20892-7982

RE: IACUC Case #2018-01 - Final Report

Dear Dr. Wolff:

I am submitting this report in accordance with the requirements of the PHS Policy at IV.F.3. The IACUC has reviewed the incident described in this report and determined it was reportable to OLAW.

1. **Animal Welfare Assurance Number:** A3294-01
2. **Grant or Contract Number:** NIH 5R01DA043164-02
3. **Species:** Nonhuman primates
4. **Effects on Programmatic or Physical Areas:** NA
5. **Explanation of the Situation:**
   a. The Principal Investigator (PI) discovered that one of three antiretroviral medications that were being administered to Nonhuman Primates (NHPs) as approved in the protocol was not the correct drug, but rather a drug with the same drug abbreviation/ initials. The error was suspected by laboratory personnel after it was noticed that the molecular weight listed on the bottle label was not correct for the intended drug.
   b. The PI also adminstered the look-alike drug once, in two animals on a separate NHP protocol, in order to confirm the presence of the intended drug. This protocol was approved to assess pharmacokinetics and safety parameters of candidate nanoART formulations in macaques. One of the expected drugs was not found, and the negative result contributed to the further investigation by the lab that one of the three antiretroviral drugs was not received.
   c. The animals animals on the original study had received the incorrect drug in an anti-retroviral combination for approximately 5 months. Upon discovery, the PI immediately contacted the IACUC and instructed the lab to discontinue administration of the incorrect drug. It should be noted that the incorrect drug has been used as a neuroprotectant.
   d. None of the animals exhibited adverse signs that could be linked to the drug. The original experiment involved 10 NHP macaques that were euthanized during the course of the study according to approved experimental and humane end

points, and in consultation with clinical veterinarians. The decision to euthanize was based solely on criteria described in the approved protocol not because of any potential ill health effects from the inadvertent administration of the incorrect drug.

e. During preliminary investigation, the PI explained that the drug mix up happened after a quote was requested from the a drug company in 2016 using the correct CAS (Chemical Abstracts Service) number and drug name. However, the quote returned by the company was for the incorrect drug and did not include the CAS number. The laboratory staff assumed that follow up correspondence was for the correct drug because their request listed the drug name and CAS number, even though only the abbreviated name/ initials were used by the company. When the drug was sent, the company had identified it with only the abbreviated name/ initials and catalogue number. The PI agreed that the lab staff should have validated the drug by looking for all the identifying information, including the CAS number which was not included, not just the abbreviation/ initials upon arrival. He had already established a standard operating protocol for the lab to validate all drugs to be administered to animals would be when received. The PI concluded that he had received the correct drug and would complete the study using the correct drug as well as plans to fully disclose the study details in any future publications.

f. The IACUC Executive Committee then met and discussed the findings of the investigation about the reported incident, including the separate investigation provided by the Protocol Assessment Liaison (PAL) to verify the details given by the PI. After reviewing all the information provided, the consensus of the executive committee was that the lab had a reasonable expectation to believe they had received the right drug and then administered what they believed was the correct drug, and that there was no evidence that the drug caused any adverse health effects to the animals. The committee agreed that the PI should continue the study according to the approved protocol but continued the investigation to confirm all of the steps described before and after the incident. They also determined that the full IACUC should be informed about the incident at the next scheduled meeting.

g. At the fully convened IACUC meeting the AV provided a summary of the incident and informed the IACUC of the ongoing investigation with plans to report those to the committee when it was complete.

h. After all the information was assembled an IACUC subcommittee was scheduled to review the incident and all IACUC members were invited to attend. The IACUC subcommittee's recommendation, after intensive review, was that animal welfare was not jeopardized. Nevertheless, the incident was verbally reported to OLAW, the USDA and AAALAC International.

6. Actions Taken by the IACUC/ IO:

a. The committee determined that additional preventative/corrective action was required of the PI/lab:

1) Personnel must ensure that all drugs are labeled clearly with accurate identifying information to prevent any additional mix ups.

2) A written plan to validate drugs when ordering, receiving, and prior to administration must be implemented. This plan should include the following information for each drug:
   i. Chemical Name
   ii. CAS Number
   iii. Molecular Formula
   iv. Formula Weight
   v. Quantity
   vi. Name and Signature of Person Validating

b. Per the Institutional Official (IO), the following actions were requested in response to incident.

1) The IACUC evaluated all correspondence between the university and the drug company to understand how and when miscommunication occurred that led to purchase and delivery of the incorrect drug.
   i. The Protocol Assessment Liaison (PAL) contacted the company that provided the drug and during discussion the company representative was able to access correspondence associated with the original quote and order request. This correspondence matched the documentation previously provided by laboratory personnel. The company representative agreed that there was a miscommunication during the quote and order process. Research personnel did request a quote and then provided the company with the correct CAS number and drug name. The company representative acknowledged receipt of the drug information and indicated that he would update the quote, but did not validate the CAS number. The incorrect drug was shipped.

2) The Office of Vice Chancellor for Research invited two external experts to review institutional practices for the procurement, labelling, storage, handling, and administration of pharmacologics used in animal research and to recommend best practices that the IACUC will develop and disseminate to UNMC investigators.
   i. The review was completed on April 16th, 2018 and the final report is pending.

3) The IACUC should re-evaluate its current policy and process for confirming experience and/or training of staff performing procedures and/or working with nonhuman primates and augment that process as necessary.
   i. A committee was formed to evaluate the verification of personnel qualifications and the training program, and recommendations are being developed.

4) The Chief Compliance Officer, with the Associate Vice Chancellor for Academic Affairs separately reviewed IACUC policies and procedures, and the events involved in the incident to determine if anything more should be done to prevent episodes like this in the future, beyond those already formulated by the IACUC and the research personnel. Once the report of the outside consultants is received, they will meet with the Chancellor and IO.

5) A NHP care team was created to further enhance the expertise, training and skill of a dedicated team of personnel involved with care and research involving nonhuman primates. This dedicated care team coordinates, performs, and provides oversight of procedures involving non-human primates.

7. Implementation Schedule:

a. All corrective/preventative actions have been completed.

If you have any questions or require any further information, please do not hesitate to contact me.

Respectfully,

(b) (6)

Jennifer Larsen, MD
Institutional Official,
University of Nebraska Medical Center
Vice Chancellor for Research
Louise and Morton Degen Professor of Internal Medicine
Administrative Assistant: (b) (6)@unmc.edu)
PH (b) (6)
FAX (b) (6)
email: jlarsen@unmc.edu

cc: Robert G. Bennett, Ph.D., IACUC Executive Chair
(b) (6)
John F. Bradfield, D.V.M., Ph.D. Attending Veterinarian/Director Comparative Medicine

Wolff, Axel (NIH/OD) [E]

From:	OLAW Division of Compliance Oversight (NIH/OD)
Sent:	Wednesday, May 23, 2018 6:06 AM
To:	Bradfield, John F
Cc:	OLAW Division of Compliance Oversight (NIH/OD)
Subject:	RE: U of Nebraska Final report 2018-01

Thank you for submitting this final report, John. I will send a response shortly.
Axel

From: Bradfield, John F [mailto:john.bradfield@unmc.edu]
Sent: Tuesday, May 22, 2018 4:08 PM
To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov>
Cc: (b) (6)@unmc.edu>
Subject: U of Nebraska Final report 2018-01

Dear Dr Wolff (Axel),

Attached is a final report of an animal care and use investigation conducted by the University of Nebraska Medical Center. You may recall that we called and reported a preliminary report. This is a follow-up to the previous report. Please let us know if you have any questions, and I hope all is well with you!

Thanks for your review and consideration,

John

John Bradfield, DVM, PhD
Director
Comparative Medicine
University of Nebraska Medical Center
985810 Nebraska Medical Center | Omaha, NE 68198-5810
W (b) (6)
F
john.bradfield@unmc.edu

A3294-3F

Office of Laboratory Animal Welfare

OLAW

Initial Report of Noncompliance

By: [redacted]

Date: 3/1/18 Time: 8:20

Name of Person reporting: Jodi Bradfield (b) (6)

Telephone #: (b) (6)

Fax #:

Email:

Name of Institution: Univ Nebraska Medical Center

Assurance number: A3294

Did incident involve PHS funded activity? Yes

Funding component: NIDA

Was funding component contacted (if necessary): _____

What happened?

SIV study on drug tx. Wrong drug given due to ordering mistake (drug has same name) Lab did not verify drug

10 animals involved, same cart changed as part of study.

No animals died but someone reported this to the media.

Species involved: ~~Macaque~~

Personnel involved:

Dates and times:

Animal deaths:

Projected plan and schedule for correction/prevention (if known): _____

Verify drug in future - ordering, receipt, administration

Check all info more carefully.

Projected submission to OLAW of final report from Institutional Official:

OFFICE USE ONLY

Case #_____

Wolff, Axel (NIH/OD) [E]

From: OLAW Division of Compliance Oversight (NIH/OD)
Sent: Wednesday, March 14, 2018 2:01 PM
To: Schermerhorn, Jen (NIH/NIDA) [E]
Cc: OLAW Division of Compliance Oversight (NIH/OD)
Subject: RE: Information for grant 5R01DA043164; PI- Howard Fox

Thank you for this communication, Ms. Schermerhorn. The institution has already contacted OLAW about this matter and we have started a case file. If you would like a copy of OLAW's response upon completion of the case, I would be happy to forward it to you.

Axel Wolff, M.S., D.V.M..
Deputy Director, OLAW

From: Schermerhorn, Jen (NIH/NIDA) [E]
Sent: Wednesday, March 14, 2018 1:45 PM
To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov>
Subject: FW: Information for grant 5R01DA043164; PI- Howard Fox

Good Afternoon,

I am writing to ensure OLAW was notified of a potential animal related issue. Please see below. If you need any additional information or I can be of assistance, do not hesitate to contact me.

Thank you,

Jennifer L. Schermerhorn
Grants Management Specialist
National Institute on Drug Abuse (NIDA)
6001 Executive Blvd.
Suite 4237B, MSC 9550
Rockville, MD 20852
Phone: 301-827-6704
schermerhornj@mail.nih.gov

Doing human subjects research?
There are new forms and updated application information
PHS Human Subjects and Clinical Trials Information Form Walk-through

From: Larsen, Jennifer L [mailto:jlarsen@unmc.edu]
Sent: Monday, March 05, 2018 2:23 PM
To: Fox, Howard S <hfox@unmc.edu>; Schermerhorn, Jen (NIH/NIDA) [E] <jen.schermerhorn@nih.gov>
Cc: Purohit, Vishnudutt (NIH/NIDA) [E] <vpurohit@nida.nih.gov>; Buch, Shilpa <sbuch@unmc.edu>; Byrareddy, Siddappa N. (siddappa.n.byrareddy@emory.edu) <siddappa.n.byrareddy@emory.edu>
Subject: Re: Information for grant 5R01DA043164; PI- Howard Fox

Correct, OLAW and USDA were contacted Thursday March 1.

Institutional Official, Animal Welfare, UNMC

Jennifer L. Larsen, MD
Vice Chancellor for Research
Louise and Morton Degen Professor of Internal Medicine
University of Nebraska Medical Center
Administrative Assistant: (b) (6) @unmc.edu)
PH (b) (6)
FAX (b) (6)
email: jlarsen@unmc.edu

From: "Fox, Howard S" <hfox@unmc.edu>
Date: Monday, March 5, 2018 at 12:15 PM
To: "Schermerhorn, Jen (NIH/NIDA) [E]" <jen.schermerhorn@nih.gov>, "Larsen, Jennifer L" <jlarsen@unmc.edu>
Cc: "Purohit, Vishnudutt (NIH/NIDA) [E]" <vpurohit@nida.nih.gov>, "Buch, Shilpa" <sbuch@unmc.edu>, "Byrareddy, Siddappa N. (siddappa.n.byrareddy@emory.edu)" <siddappa.n.byrareddy@emory.edu>
Subject: Re: Information for grant 5R01DA043164; PI- Howard Fox

Thank you. OLAW has been notified, and I have copied our institutional official, Dr. Larsen, to be sure.
Howard

Sent from my iPhone

On Mar 5, 2018, at 11:43 AM, Schermerhorn, Jen (NIH/NIDA) [E] <jen.schermerhorn@nih.gov> wrote:

> Non-UNMC email
>
> Good Afternoon Vishnu,
>
> The PIs will need to have the institutional officials notify OLAW for further guidance on this issue.
>
> Vishnu- please notify your branch chief so that the Communications office can prepare if needed.
>
> Thank you,
>
> *Jennifer L. Schermerhorn*
> Grants Management Specialist
> National Institute on Drug Abuse (NIDA)
> 6001 Executive Blvd.
> Suite 4237B, MSC 9550
> Rockville, MD 20852
> Phone: 301-827-6704
> schermerhornj@mail.nih.gov
> Doing human subjects research? <image001.png>
> There are new forms and updated application information
> PHS Human Subjects and Clinical Trials Information Form Walk-through

From: Purohit, Vishnudutt (NIH/NIDA) [E]
Sent: Thursday, March 01, 2018 11:51 AM
To: Schermerhorn, Jen (NIH/NIDA) [E] <jen.schermerhorn@nih.gov>
Subject: Information for grant 5R01DA043164; PI- Howard Fox

Hi Jennifer:

Regarding some potential issue with PETA

FYI and advice.

Vishnu

From: Fox, Howard S [mailto:hfox@unmc.edu]
Sent: Wednesday, February 28, 2018 11:37 PM
To: Purohit, Vishnudutt (NIH/NIDA) [E] <vpurohit@nida.nih.gov>
Cc: Buch, Shilpa <sbuch@unmc.edu>; Byrareddy, Siddappa <sid.byrareddy@unmc.edu>
Subject: Information for grant 5R01DA043164

Hi Vishnu. As contact PIs, I have some important information regarding this study (The brain as a SIV reservoir under suppressive cART potentiation by drugs of abuse).
As part of the animal studies, we are treating SIV-infected animals with combination antiretroviral therapy (tenofovir TFV, emtricitabine FTC, and dolugetravir DTG). Unfortunately, instead of dolutegravir (DTG) the drug we were administering was labeled DTG but was in fact 1,3-Di-(2-tolyl)guanidine, a drug that acts on the sigma receptor. The other two antiretrovirals were indeed given.
Upon realizing this we stopped that drug and reported it to our veterinary staff and the IACUC. We supplied all information to the IACUC (including viral loads, drug levels measured by mass spec, communication, and other information). I am doing most of the communication, as it was my group that procured the drugs. The IACUC determined today that as there was no evidence that animals were harmed and that "this concern did not constitute reportable noncompliance, but at the same time recognized that an inadvertent error had been made by the lab and R&D Systems. In addition the subcommittee requested that a corrective/preventative action plan be implemented immediately." This was their recommendation to be made to our institutional official, who will make the final determination of action and reporting.
Unfortunately someone today notified the local newspaper, claiming to be from PETA, with some of the information but also with some incorrect information. Our attending veterinarian will make OLAW and the USDA aware of this all, and we will continue our internal process. We are meeting with the reporter tomorrow, and fully expect this to lead to a story, and not at all sure what will happen regarding PETA. But wanted to make you aware, and happy to chat, supply any additional information now, as well as keep you informed as this develops.
Howard Fox (on behalf of the other multiple-PIs, Shilpa Buch and Sid Byrareddy)

========

Howard S. Fox, M.D., Ph.D.
Senior Associate Dean of Research and Development, College of Medicine
Professor and Executive Vice Chair, Department of Pharmacology and Experimental Neuroscience
Director of the Center for Integrative and Translational Neuroscience
phone: (b) (6)

Please contact (b) (6) for appointments and administrative matters:

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

A3294 -

AN INTERNATIONAL ORGANIZATION DEDICATED TO PROTECTING THE RIGHTS OF ALL ANIMALS

PETA

PEOPLE FOR
THE ETHICAL
TREATMENT
OF ANIMALS

Washington, D.C.
1536 16th St. N.W.
Washington, DC 20036
202-483-PETA

Los Angeles
2154 W. Sunset Blvd.
Los Angeles, CA 90026
323-644-PETA

Norfolk
501 Front St.
Norfolk, VA 23510
757-622-PETA

Oakland
554 Grand Ave.
Oakland, CA 94610
510-763-PETA

Info@peta.org
PETA.org

February 28, 2018

Brent Morse, DVM
Acting Director
Division of Compliance Oversight
Office of Laboratory Animal Welfare

Via e-mail: Brent.Morse@nih.gov

Dear Dr. Morse:

I am writing on behalf of People for the Ethical Treatment of Animals (PETA) and our more than 6.5 million members and supporters to request that the Office of Laboratory Animal Welfare (OLAW) investigate disturbing allegations regarding the mistreatment of nonhuman primates at the University of Nebraska Medical Center (UNMC; PHS Assurance D16-00189, A3294-01), located at 985810 Nebraska Medical Center in Omaha, Neb. If true, the allegations suggest potential noncompliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy) and the Guide for the Care and Use of Laboratory Animals (the *Guide*).

PETA was recently contacted by an anonymous insider at UNMC who informed us that about four weeks ago, at least five monkeys died when a technician injected the incorrect antiretrovirals into SIV-infected monkeys. As many as 12 monkeys may have been injected with the incorrect antiretrovirals. It appears that the incorrect compound was used to prepare the injections. The compound that should have been used would have decreased the viral loads, but instead, the virus kept on multiplying at high levels. This resulted in some "pathology around the skull." It is unclear whether the error was made by a technician or by a person ordering the reagent—or whether a series of careless mistakes had been committed. The problem may also have stemmed from the pH of the injections. However, the insider maintains that using the incorrect reagent repeatedly was reckless.

The monkeys who were subjected to the faulty injections were being used in Principal Investigator Howard S. Fox's experimental protocol, "The Brain as a SIV Reservoir Under Suppressive Cart Potentiation by Drugs of Abuse," which is supported by the National Institute of Drug Abuse. In this protocol, Fox administers different drugs of abuse—including methamphetamines and opiates—to SIV-infected monkeys and then treats the monkeys with anti-retroviral treatments.

While the alleged monkey deaths indicate UNMC's failure to avoid or minimize "discomfort, distress, and pain" to animals, in noncompliance with principles endorsed by the *Guide,* the error(s) made by the employees involved in ordering, formulating, and/or injecting the antiretroviral further suggest UNMC's failure to ensure that personnel conducting procedures are qualified to perform their duties, in noncompliance with the *Guide*.

Affiliates:
- PETA Foundation (U.K.)
- PETA AsiaPacific
- PETA India
- PETA Germany
- PETA Netherlands

We also understand that in a separate laboratory at UNMC, two monkeys were used in lymph node biopsies; but the wounds are not healing properly and the stiches are coming undone. The insider believes this is either because the sutures may have been knotted incorrectly or because personnel failed to adequately monitor the monkeys following the biopsies. If accurate, either scenario suggests failure to comply with the *Guide*.

We urge you to investigate the claims summarized in this letter and, if the claims are substantiated, take swift action to ensure that UNMC implements measures to prevent recurrence of the alleged problems.

If you have any questions, please contact me at (b) (6) or AlkaC@peta.org. Thank you for your time and consideration.

Sincerely,

(b) (6)

Alka Chandna, Ph.D.
Chief, Laboratory Case Management
Laboratory Investigations Department
People for the Ethical Treatment of Animals

Morse, Brent (NIH/OD) [E]

From: Morse, Brent (NIH/OD) [E]
Sent: Tuesday, March 06, 2018 1:20 PM
To: 'Dr. Alka Chandna'
Subject: RE: Concerns regarding treatment of nonhuman primates at the University of Nebraska Medical Center:

Hello Dr. Chandna,

OLAW acknowledges receipt of your letter dated February 28, 2018. We will investigate the allegations and take any appropriate actions.

Regards, Brent Morse

Brent C. Morse, DVM, DACLAM
Acting Director
Division of Compliance Oversight
Office of Laboratory Animal Welfare
National Institutes of Health

From: Dr. Alka Chandna [mailto:AlkaC@peta.org]
Sent: Wednesday, February 28, 2018 9:24 PM
To: Morse, Brent (NIH/OD) [E] <morseb@mail.nih.gov>
Subject: Concerns regarding treatment of nonhuman primates at the University of Nebraska Medical Center:

Dear Dr. Morse,

I hope this correspondence finds you well. Please find attached a letter from PETA, summarizing our concerns related to the treatment of nonhuman primates at the University of Nebraska Medical Center, as alleged to us by a university insider. Thank you for your attention to this matter.

Sincerely,

Alka Chandna

Alka Chandna, Ph.D.
Chief, Laboratory Case Management
Laboratory Investigations Department
People for the Ethical Treatment of Animals
1536 16th Street NW, Washington, DC 20036

The more we learn of the true nature of non-human animals, especially those with complex brains and corresponding complex social behavior, the more ethical concerns are raised regarding their use in the service of man -- whether this be in entertainment, as "pets," for food, in research laboratories, or any of the other uses to which we subject them. – Dr. Jane Goodall